Tashiro T
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
Gan To Kagaku Ryoho. 1992 Oct;19(12):2107-12.
Selective toxicity against cancer cells is a most important determinant for anticancer agents. Therefore, we have preferably evaluated anticancer effects in vivo using murine tumor models for several decades. Approximately 50 anticancer agents are currently available for clinical therapy, but very few agents are effective against some types of cancer. Much progresses in cell culture techniques resulted in establishment of various human tumor cell lines. Currently, we are able to use human tumor lines as well as murine ones for the examination of drug sensitivity. A number of assay methods to evaluate anticancer activity have been developed. In the beginning, growth inhibitory activity was evaluated by counting cell numbers after drug exposure. Then, human tumor clonogenic assay (HTCA) was designed to measure only proliferative cells. Recently colorimetric MTT assay and SRB assay in 96-well microplates were developed, which were adopted in the screening system in the NCI, based on a new idea, that is, disease-oriented screening (DOS) using about 60 human tumor cell lines. In this paper outline of each method was described, adding especially several comments on disease-oriented screening.
对癌细胞的选择性毒性是抗癌药物最重要的决定因素。因此,几十年来我们一直优先使用小鼠肿瘤模型在体内评估抗癌效果。目前约有50种抗癌药物可用于临床治疗,但对某些类型癌症有效的药物非常少。细胞培养技术的巨大进步促成了各种人类肿瘤细胞系的建立。目前,我们能够使用人类肿瘤细胞系以及小鼠肿瘤细胞系来检测药物敏感性。已经开发出许多评估抗癌活性的测定方法。起初,通过在药物处理后计数细胞数量来评估生长抑制活性。然后,设计了人类肿瘤克隆形成试验(HTCA)来仅测量增殖细胞。最近,96孔微孔板中的比色MTT试验和SRB试验被开发出来,并基于一种新的理念,即使用约60种人类肿瘤细胞系的疾病导向筛选(DOS),被应用于美国国立癌症研究所的筛选系统。本文描述了每种方法的概述,并特别对疾病导向筛选添加了一些评论。